Narrow Dental Implants in Multiple Fixed Prosthesis: A Controlled Clinical Trial (NCT04006782) | Clinical Trial Compass
Active — Not RecruitingNot Applicable
Narrow Dental Implants in Multiple Fixed Prosthesis: A Controlled Clinical Trial
Spain48 participantsStarted 2019-08-01
Plain-language summary
The objective of this study is to evaluate the survival of narrow dental implants (≤ 3,5 mm) in multiple fixed prostheses in comparison with standard diameter dental implants (≥ 3,75 mm) after 5 years of follow-up. The hypothesis of the study is that narrow dental implants under the evaluated conditions, have the same survival rate and clinical performance than the standard diameter implants.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Patients of legal age (\>18 years) of both sexes.
* Clinical need of multiple fixed alveolar ridge rehabilitations.
* Clinical suitability to insert, at least, one narrow dental implant splinted to a standard diameter dental implant.
* Signature of the informed consent
Exclusion Criteria:
* Presence of an active infection
* Being under active treatment with, or have received in the las 30 days treatment with radiotherapy, chemotherapy, immunosuppressors, systemic corticosteroids and/or anticoagulants.
* Presence of severe haematologic disorders.
* Chronic treatment with non steroidal anti-inflammatory drugs (NSAID) or other aniinflammatory drugs.
* Previous diagnosis of chronic hepatitis or liver cirrhosis.
* Presence of Diabetes mellitus with improper metabolic control (glycosylated haemoglobine higher that 9%).
* Patients subjected to dialysis.
* Presence of malignant tumours, haemangioma or angioma in the surgical area.
* History of ischaemic cardiopathy in the las year.
* Pregnancy or plan to getting pregnant during the study.
* Metabolic bone disease
* Patientd receiving treatment with oral or intravenous biphosphonates.
* Any other condition incompatible with the participation in the study,
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Survival after 5 years of follow-up
Timeframe: 5 years in comparison with the baseline